

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
(Translated from Hebrew)

	September 30		December 31
	2020	2019	2019
	NIS in thousands		
Assets			
CURRENT ASSETS:			
Cash and cash equivalents	28,520	31,102	28,392
Receivables:			
Trade receivables	4,572	3,528	3,925
Other receivables	6,143	1,056	1,934
Current tax assets	1,079	-	363
Inventory	19,794	12,872	12,195
Biological assets	5,121	2,197	1,957
	65,229	50,755	48,766
NON-CURRENT ASSETS:			
Property, plant and equipment	11,515	7,015	8,699
Operating lease right of use assets	1,693	1,613	1,932
Investments in associates	4,421	2,271	1,474
Financial assets	6,896	4,746	6,257
	24,525	15,645	18,362
TOTAL ASSETS	89,754	66,400	67,128
Liabilities and equity			
CURRENT LIABILITIES -			
Accounts payable:			
Trade payables	1,042	1,045	876
Other payables	2,137	1,388	1,492
Deferred and contingent liabilities	6,720	13,885	13,533
Current tax liability	-	365	-
	9,899	16,683	15,901
NON-CURRENT LIABILITIES:			
Deferred tax liability	3,590	2,555	2,571
Operating lease liabilities	1,294	1,459	1,782
Retirement benefits liabilities, net	113	90	113
	4,997	4,104	4,466
EQUITY:			
Share capital and share premium	62,140	49,322	49,430
Other equity reserves	8,260	1,947	1,241
Accumulated earnings (loss)	4,458	(5,656)	(3,910)
	74,858	45,613	46,761
TOTAL LIABILITIES AND EQUITY	89,754	66,400	67,128

Seach*

MEDICAL GROUP

CONSOLIDATED INCOME STATEMENTS

(Translated from Hebrew)

	NINE MONTHS ENDED IN SEPTEMBER 30		THREE MONTHS ENDED IN SEPTEMBER 30		YEAR ENDED IN
	2020	2019	2020	2019	2019
	NIS in thousands				
Revenue from sales	25,805	22,017	6,575	9,073	28,834
Cost of sales	10,609	9,450	2,819	3,263	14,970
GROSS PROFIT BEFORE FAIR VALUE ADJUSTMENTS	15,196	12,567	3,756	5,810	13,864
Unrealized gain on changes in fair value of biological assets	10,632	6,549	2,706	1,437	7,962
Fair value changes in biological assets sold	(7,745)	(7,596)	(1,840)	(3,038)	(8,082)
GROSS PROFIT AFTER FAIR VALUE ADJUSTMENTS	18,083	11,520	4,622	4,209	13,744
Research and development expenses	1,355	1,273	434	700	1,806
Sales and marketing expenses	2,092	1,447	643	512	2,078
General and administrative expenses	5,528	3,940	1,809	1,435	5,238
Listing cost of reverse acquisition	-	28,765	-	28,765	28,765
Loss from disposal and decrease in holding stake in associates	886	373	303	(64)	783
Other income	(2,881)	(930)	(481)	(911)	(876)
OPERATING INCOME (LOSS)	11,103	(23,348)	1,914	(26,228)	(24,050)
Finance expenses	1,069	506	28	277	468
Finance income	101	55	1,031	38	3,531
Financial (income) expenses, net	968	451	(1,003)	239	(3,063)
INCOME (LOSS) BEFORE TAXES	10,135	(23,799)	2,917	(26,467)	(20,987)
Tax expenses	1,767	501	594	(385)	1,567
NET INCOME (LOSS)	8,368	(24,300)	2,323	(26,082)	(22,554)
OTHER COMPREHENSIVE INCOME (LOSS)					
Items that will be reclassified into profit or loss -					
Translation differences, net	-	-	-	-	(1)
Items that will not be reclassified into profit or loss -					
Profit (loss) from financial assets at fair value, net of tax	364	(646)	(549)	(446)	(1,518)
TOTAL OTHER COMPREHENSIVE INCOME (LOSS), NET OF TAX	364	(646)	(549)	(446)	(1,519)
TOTAL COMPREHENSIVE PROFIT (LOSS)	8,732	(24,946)	1,774	(26,528)	(24,073)
PROFIT (LOSS) PER SHARE ATTRIBUTABLE TO SHAREHOLDERS OF THE COMPANY:					
Basic and diluted	0.03	(0.10)	0.01	(0.11)	(0.08)